2235.5000 -51.40 (-2.25%)
NSE Jul 17, 2026 15:31 PM
Volume: 356.0K
 

2235.50
-2.25%
Deven Choksey
We have revised our FY26E/FY27E EPS estimates by -1.1 %/+13.2%, respectively, as we factor in improvement in EBITDA margins on account of improving mix and launch of high margin products.
Glenmark Pharmaceuticals Ltd. is trading below its 50 day SMA of 2247.7
More from Glenmark Pharmaceuticals Ltd.
Recommended